Brain insulin differences in schizophrenia and thinking
Treatments studied
Part of Hormones & metabolism, Mental health clinical trials.
This study tests whether unusual insulin action in the brain is linked to thinking problems and body/metabolic issues in schizophrenia. It may help researchers understand the cause and identify targets for future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 17 to 45
- If you have schizophrenia-spectrum illness: diagnosis must be confirmed by medical record review
- Body mass index (BMI) 27 or less
- You must be able to do MRI/PET scans without metal or breathing/space-related problems
- You cannot have prediabetes or diabetes, based on an oral glucose tolerance test (OGTT)
- No pregnancy, nursing, or significant substance misuse
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how a natural chemical pathway in the body might relate to thinking problems in people with schizophrenia. It compares healthy volunteers to people with schizophrenia to find biological clues.
This study tests whether a type of brain stimulation called intermittent theta burst stimulation (iTBS) can help improve social thinking and understanding in people with psychosis. Researchers want to see if this treatment can boost how you read social cues and connect with others.
This study uses brain scans (MRI and PET) to look at energy use and a brain chemical called glutamate in people with schizophrenia. It compares healthy volunteers to those with well-controlled schizophrenia and those with hard-to-treat schizophrenia to understand the biology better.
This trial tests whether bromocriptine can help people who have schizophrenia and prediabetes (higher-than-normal blood sugar but not diabetes). You may be able to join if your blood sugar and other health factors fit the study rules.
This study tests whether a single dose of a common antipsychotic medication affects how the brain responds to insulin, which could help explain weight gain and metabolic side effects. Healthy young adults will receive either the antipsychotic or a placebo, then have their brain activity measured with an MRI.
This study looks at how a common antipsychotic medication (olanzapine) affects how the brain uses insulin in young women. It aims to understand weight gain and metabolic changes linked to these drugs.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.